Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma

[1]  Seung‐Mo Hong,et al.  Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma , 2016, Journal of Gastrointestinal Surgery.

[2]  Gaofeng Li,et al.  MDK Protein Overexpression Correlates with the Malignant Status and Prognosis of Non-small Cell Lung Cancer. , 2015, Archives of medical research.

[3]  Jun Zhang,et al.  The clinical and prognostic significance of midkine in breast cancer patients , 2015, Tumor Biology.

[4]  E. Cho,et al.  CD44 expression in patients with combined hepatocellular cholangiocarcinoma , 2015, Annals of surgical treatment and research.

[5]  Nu Zhang,et al.  Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK) , 2015, Molecular biology of the cell.

[6]  Seung Duk Lee,et al.  Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[7]  R. Simon,et al.  The Multifunctional Growth Factor Midkine Promotes Proliferation and Migration in Pancreatic Cancer , 2014, Molecular Cancer Research.

[8]  T. Muramatsu,et al.  Midkine: an emerging target of drug development for treatment of multiple diseases , 2014, British journal of pharmacology.

[9]  K. Rau,et al.  Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma , 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  Gi Jeong Kim,et al.  Increased Expression of Yes-Associated Protein 1 in Hepatocellular Carcinoma with Stemness and Combined Hepatocellular-Cholangiocarcinoma , 2013, PloS one.

[11]  S. Kishida,et al.  The heparin-binding growth factor midkine: the biological activities and candidate receptors. , 2013, Journal of biochemistry.

[12]  X. Wang,et al.  Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[13]  Chi-Chih Wang,et al.  Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma. , 2013, Surgical oncology.

[14]  W. Cong,et al.  Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular‐cholangiocarcinoma , 2012, Hepatology.

[15]  K. Sakamoto,et al.  Midkine in the pathology of cancer, neural disease, and inflammation , 2012, Pathology international.

[16]  J. Izbicki,et al.  Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. , 2011, Cancer research.

[17]  Zengliang Li,et al.  [The latest 2010 WHO classification of tumors of digestive system]. , 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[18]  Chao-Wei Lee,et al.  Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. , 2011, Asian journal of surgery.

[19]  M. Taura,et al.  Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma. , 2010, International journal of oncology.

[20]  J. Llovet,et al.  New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers , 2010, Clinical Cancer Research.

[21]  H. Iwase,et al.  Midkine in plasma as a novel breast cancer marker , 2009, Cancer science.

[22]  I. Kodama,et al.  Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. , 2009, American journal of physiology. Heart and circulatory physiology.

[23]  H. Lee,et al.  Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma , 2009, Annals of Surgical Oncology.

[24]  N. Yaegashi,et al.  Midkine and its clinical significance in endometrial carcinoma , 2008, Cancer science.

[25]  F. Zhang,et al.  Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double‐fluorescence immunostaining evidence , 2007, Histopathology.

[26]  M. Matsuda,et al.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.

[27]  S. Ng,et al.  Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging , 2007, International journal of clinical practice.

[28]  Qing-Yun Zhang,et al.  Expression of midkine and its clinical significance in esophageal squamous cell carcinoma. , 2006, World journal of gastroenterology.

[29]  T. Muramatsu,et al.  Midkine, a heparin-binding growth factor, produced by the host enhances metastasis of Lewis lung carcinoma cells. , 2006, Cancer letters.

[30]  Kazuhiro Yoshida,et al.  A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[31]  T. Muramatsu,et al.  Serum midkine concentrations and gastric cancer , 2005, Cancer science.

[32]  C. Toh,et al.  Combined hepatocellular‐cholangiocarcinoma: a case report , 2004, International journal of clinical practice.

[33]  H. Matsubara,et al.  Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma , 2003, Cancer science.

[34]  M. Makuuchi,et al.  Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. , 2003, Japanese journal of clinical oncology.

[35]  H. Matsubara,et al.  Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. , 2003, Oncology reports.

[36]  M. Ladanyi,et al.  Combined Hepatocellular–Cholangiocarcinoma: A Histopathologic, Immunohistochemical, and In Situ Hybridization Study , 2002, The American journal of surgical pathology.

[37]  S. Tickoo,et al.  Combined hepatocellular and cholangiocarcinoma , 2002, Cancer.

[38]  K. Endo,et al.  Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and in situ hybridization analyses. , 2000, Liver.

[39]  T. Terada,et al.  Increased midkine expression in hepatocellular carcinoma. , 2000, Archives of pathology & laboratory medicine.

[40]  Lily T Ma,et al.  Combined hepatocellular‐cholangiocarcinoma: A clinicopathological study , 1998, Journal of gastroenterology and hepatology.

[41]  M. Kojiro,et al.  A Clinicopathological study on combined hepatocellular and cholangiocarcinoma , 1996, Journal of gastroenterology and hepatology.

[42]  M. Tsuneyoshi,et al.  Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. , 1995, Human pathology.

[43]  R. Allen,et al.  Combined liver cell and bile duct carcinoma. , 1949, The American journal of pathology.

[44]  S. Fan,et al.  Hepatic resection for combined hepatocellular and cholangiocarcinoma. , 2003, Archives of surgery.

[45]  F. Greene,et al.  AJCC cancer staging handbook : from the AJCC cancer staging manual , 2002 .

[46]  Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. , 1990, Annals of surgery.

[47]  K. Ishak,et al.  Combined hepatocellular‐cholangiocarcinoma. A histologic and immunohistochemical study , 1985, Cancer.